Weekly administration of gemcitabine and docetaxel combinations in the treatment of advanced non-small cell lung cancer / 中国肺癌杂志
Zhongguo fei'ai zazhi (Online)
; Zhongguo fei'ai zazhi (Online);(12): 375-377, 2003.
Article
en Zh
| WPRIM
| ID: wpr-345885
Biblioteca responsable:
WPRO
ABSTRACT
<p><b>BACKGROUND</b>To evaluate the efficacy and side effects of weekly administration of gemcitabine combined with docetaxel in the treatment of advanced non-small cell lung cancer.</p><p><b>METHODS</b>Twenty-six patients with advanced non-small cell lung cancer, with or without prior chemotherapy, were entered into this study. Gemcitabine and docetaxel were administrated weekly for 3 consecutive weeks, followed by 1 week rest. Gemcitabine was given as 800-1 200 mg/m² by intravenous infusion on days 1, 8, 15; while docetaxel was 35 mg/m² intravenously on the same days as gemcitabine. The efficacy including response rate and median survival duration and toxicity were observed.</p><p><b>RESULTS</b>Of the 26 patients, one achieved complete response (CR), and 6 achieved partial response (PR), with an overall response rate of 27%. The median survival duration was 9.5 months and 1-year survival rate was 38% (10/26). The main toxicities were neutropenia and thrombocytopenia. One patient died from allergic shock.</p><p><b>CONCLUSIONS</b>The combination of docetaxel and gemcitabine is effective and well-tolerated in the treatment of advanced NSCLC.</p>
Texto completo:
1
Base de datos:
WPRIM
Idioma:
Zh
Revista:
Zhongguo fei'ai zazhi (Online)
Año:
2003
Tipo del documento:
Article